Tradename: ODACTRA
Proper Name: House Dust Mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus) Allergen Extract
Indication: To include use in adolescents 12 through 17 years of age.
ODACTRA is an allergen extract indicated as immunotherapy for the treatment of house dust mite (HDM)-induced allergic rhinitis, with or without conjunctivitis, confirmed by positive in vitro testing for IgE antibodies to Dermatophagoides farinae or Dermatophagoides pteronyssinus house dust mites or by positive skin testing to licensed house dust mite allergen extracts. ODACTRA is approved for use in persons 12 through 65 years of age.
Approval Date: 01/20/2023
Manufacturer: ALK-Abello A/S
More: https://www.fda.gov/vaccines-blood-biologics/allergenics/odactra